US FDA Says No New Conclusions on GlaxoSmithKline’s (JOBS) Avandia Yet

Reuters -- The U.S. Food and Drug Administration is reviewing data on possible heart risks with GlaxoSmithKline Plc's (GSK.L) diabetes drug Avandia but has not reached any new conclusions, the agency said on Monday.